---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014365"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:01:15.023056+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa Q1 2023: cash $103.9M, no debt; Phase 2 trials initiated/expanded

## Summary
- Ended Q1 2023 with $103.9M cash and cash equivalents, zero debt.
- Operating expenses $7.1M (up 50% YoY); R&D $3.5M (+134%) on (Z)-endoxifen trials.
- Initiated Phase 2 EVANGELINE and new I-SPY 2 arm for (Z)-endoxifen in ER+/HER2- breast cancer.
- Full enrollment of Phase 2 KARISMA breast density study expected by end of 2023.
- US patent granted for (Z)-endoxifen enteric capsule (No. 11,572,334).

## SEC filing metadata
- accession: 0001437749-23-014365
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/0001437749-23-014365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/atos20230508_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014365
- JSON: https://secwatch.observer/filing/0001437749-23-014365.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014365.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2023.
  - Period: fiscal quarter ended March 31, 2023
  - Result: reported results
  source text: Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/0001437749-23-014365-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.